Showing all 4 results

590.00 Excl. VAT

OctopusyX BioConsulting (Olivier REVELANT, @octopusyx2), a member of Eurobiomed, and BioPharmAnalyses (Anne-Lise BERTHIER, @anneliseberthie) are proud to announce the launch of their new report entitled "AAV-based Gene Therapy Products: Ongoing Clinical Trials". This >200 pages report provides a unique exhaustive overview of 116 ongoing trials for the treatment of 40 diseases (as of June 2020). More thant 80 AAV based products described. Wishing to identify hot research topics  in this highly competitive field ?   Looking for an update on the clinical portfolio ?   Needing insights to assist you in your decision-making  or to identify the most advanced companies in the field ?   Searching for new candidates to in-license ?   ● 205 pages detailing 116 clinical trials for the treatment of 40 diseases   ● 49 companies and academic institutions developing more than 80 AAVbased gene therapy products in a wide range of therapeutic areas (Cardiovascular Diseases, Hematological Diseases, Hepatic Diseases, Infectious Diseases, inherited Metabolic Diseases, Lysosomal Diseases, Neurological Diseases, Neuromuscular Diseases and Ophthalmological Diseases) Want to have a look at this report ? Click to download sample pages ( Order Form (

3,490.00 Excl. VAT

BioPharmAnalyses and OctopusyX BioConsulting are proud to announce the launch of their up-dated and enriched 2019 edition of their report entitled « Landscape in Gene Therapy Companies » In this 800-pages report, a must-have read one, you will find -More than 230 closely scrutinized companies -More than 600 products identified including more than 200 products at the clinical stage -More than 300 VC or investors mentioned -Mor than 200 pathologies referred -A detailed Overview of Companies involved in AAV-based gene therapy, LV-based Gene Therapy, Gene Therapy, CDMO (Contracts, Manufacturing Organisation) and a Miscellaneous section including Hubs and Non Viral Gene Transfer) CAR-T strategies will be dealt separately in the updated edition of our Briefing on CAR-T clinical trials. The 2019 edition will be published next November For further information, or  

5,990.00 Excl. VAT

Gene therapy is a rapidly and obviously evolving field that is now definitively recognized as a well-acknowledged major medical and scientific area. OctopusyX BioConsulting and BioPharmAnalyses are proud to announce the launch of iheir new global commercial report “Landscape in Gene Therapy Companies“. This is the first such report that provides you with an actually updated information and an accurate international mapping [...]